Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

Gene Therapy

Volumn 17, Issue 8, 2010, Pages 961-971

  Kuhn, A N ^a   Diken, M ^a   Kreiter, S ^a   Selmi, A ^a   Kowalska, J ^b   Jemielity, J ^b   Darzynkiewicz, E ^b   Huber, C ^a   Türeci, Ö ^a   Sahin, U ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF WARSAW   (Poland)

Author keywords

cap analog; dendritic cells; RNA; vaccination

Indexed keywords

MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; RECOMBINANT ANTIGEN; RNA; RNA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CANCER VACCINES; DENDRITIC CELLS; GENES, REPORTER; HALF-LIFE; HUMANS; LUCIFERASES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PROTEIN BIOSYNTHESIS; RNA; RNA CAP ANALOGS; RNA STABILITY; VACCINES, SYNTHETIC;

MUS;

EID: 77955658245     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.52     Document Type: Article

References (33)

1. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA-and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115: 33-42.
2. Yamamoto A, Kormann M, Rosenecker J, Rudolph C. Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 2009; 71: 484-489.
3. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008; 183: 221-235.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
5. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117: 1195-1203.
6. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55: 1432-1442.
7. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 2007; 14: 1175-1180.
8. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31: 180-188.
9. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32: 498-507.
10. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174: 3798-3807.
11. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235: 540-549.
12. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003; 18: 343-354.
13. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108: 4009-4017.
14. Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 2008; 180: 309-318.
15. Cougot N, van Dijk E, Babajko S, Seraphin B. Cap-tabolism. Trends Biochem Sci 2004; 29: 436-444.
16. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731-745.
17. Pasquinelli AE, Dahlberg JE, Lund E. Reverse 5 caps in RNAs made in vitro by phage RNA polymerases. RNA 1995; 1: 957-967.
18. Grudzien E, Stepinski J, Jankowska-Anyszka M, Stolarski R, Darzynkiewicz E, Rhoads RE. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004; 10: 1479-1487.
19. 00 cap analogs with superior translational properties. RNA 2003; 9: 1108-1122.
20. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel 'anti-reverse' cap analogs 7-methyl(3-O-methyl)GpppG and 7-methyl (3-deoxy)GpppG. RNA 2001; 7: 1486-1495.
21. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007; 13: 1745-1755.
22. Kowalska J, Lewdorowicz M, Zuberek J, Grudzien-Nogalska E, Bojarska E, Stepinski J et al. Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS. RNA 2008; 14: 1119-1131.
23. Mockey M, Gonçalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006; 340: 1062-1068.
24. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E et al. Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 2006; 17: 1027-1035.
25. Grudzien E, Kalek M, Jemielity J, Darzynkiewicz E, Rhoads RE. Differential inhibition of mRNA degradation pathways by novel cap analogs. J Biol Chem 2006; 281: 1857-1867.
26. Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatino-vich J, Calderhead D et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 2008; 9: 90.
27. Türeci O, Bian H, Nestle FO, Raddrizzani L, Rosinski JA, Tassis A et al. Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J 2003; 17: 836-847.
28. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 1996; 157: 1823-1826.
29. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005; 12: 772-782.
30. Kreiter S, Konrad T, Sester M, Huber C, Türeci O, Sahin U. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother 2007; 56: 1577-1587.
31. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2006.
32. Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C, Türeci O. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res 2007; 67: 9528-9534.
33. Koslowski M, Sahin U, Dhaene K, Huber C, Türeci O. MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. Cancer Res 2008; 68: 3458-3466.